The specific mechanism of action is that the deletion of USP22 results in reduced levels of PU.1 under Kras mutation-driven MPN conditions, whereas previous studies have shown that reduced PU.1 expression and activity is common in mouse and human acute myeloid leukemia (AML) cases. Here, KRAS is linked to myeloproliferative disorder.